2-[(3S,5R,6S)-1-[(1S)-2-tert-butylsulfonyl-1-cyclopropylethyl]-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl]-N-phenylacetamide

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 2-[(3S,5R,6S)-1-[(1S)-2-tert-butylsulfonyl-1-cyclopropylethyl]-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl]-N-phenylacetamide
• 化学式: C₃₅H₄₀Cl₂N₂O₄S
• 分子量: 655.7
• InChiKey: LXLAALURXKPNDV-PZAYWHPNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  44
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  91.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• BENZOIC ACID DERIVATIVE MDM2 INHIBITOR FOR THE TREATMENT OF CANCER
  申请人：AMGEN INC.

  公开号：US20140243372A1

  公开（公告）日：2014-08-28

  The present invention provides a MDM2 inhibitor compound, or a pharmaceutically acceptable salt thereof, which compound is useful as a therapeutic agent, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contains the MDM2 inhibitor.

  本发明提供了一种MDM2抑制剂化合物，或其药用可接受的盐，该化合物可作为治疗剂，特别是用于癌症治疗。本发明还涉及含有MDM2抑制剂的药物组合物。
• Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
  申请人：AMGEN INC.

  公开号：US10881648B2

  公开（公告）日：2021-01-05

  The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.

  本发明提供了包括MDM2抑制剂和一种或多种额外的药学活性剂的组合疗法，特别是用于治疗癌症的组合疗法。 本发明还涉及用于治疗癌症的包含 MDM2 抑制剂和一种或多种额外药学活性剂的药物组合物。
• A BENZOIC ACID DERIVATIVE MDM2 INHIBITOR FOR THE TREATMENT OF CANCER
  申请人：Amgen Inc.

  公开号：EP2961735B1

  公开（公告）日：2017-09-27
• COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS
  申请人：AMGEN INC.

  公开号：US20160287569A1

  公开（公告）日：2016-10-06

  The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
• Combination Therapy Including an MDM2 Inhibitor and One or More Additional Pharmaceutically Active Agents for the Treatment of Cancers
  申请人：AMGEN INC.

  公开号：US20190290630A1

  公开（公告）日：2019-09-26

  The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.